News Archive

COLUMBIA, Md., (May 29, 2024) — TEDCO, Maryland’s economic engine for technology companies, unveiled the recently completed “Cybersecurity Workforce Analysis and Study” (“Study”). The Study was commissioned by TEDCO to better understand the current status of Maryland’s cybersecurity workforce pipeline. This knowledge will be used to guide the Cyber Maryland Program (“Program”) and its 18-member board of directors as they develop a statewide cybersecurity workforce development strategic plan.

“The Study confirms what businesses and government agencies in Maryland already know: demand for skilled cybersecurity professionals—who protect our communities from criminals threatening our way of life—is incredibly nuanced. Thankfully, there is support and momentum amongst key stakeholders to bridge our talent gap,” said Roger Austin, chair of the Cyber Maryland board of directors. “My fellow board members and I are committed to address this critical need by developing innovative solutions to overcome our cyber skills talent gaps and provide good, paying jobs for our state’s residents.”

COLUMBIA, Md. (May 30, 2024) – The Maryland Stem Cell Research Commission (“the Commission”) announces the release of Requests for Applications (RFAs) for the Maryland Stem Cell Research Fund’s (MSCRF) first funding cycle of fiscal year 2025 (FY25).

RFAs for this initial cycle are now available for five grant programs: Manufacturing Assistance, Clinical, Validation, Commercialization, and Launch. All applications are due by July 9, 2024.

Along with this announcement comes the news that the Commission is also extending grant funding to businesses outside of Maryland for the Commercialization grant program, provided the research activities are conducted within the State. The Clinical grant program is available to entities with at least one clinical site in Maryland.

GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) — Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced the clearance of its second Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for GIM-531, a first-in-class oral treatment that selectively targets T-regulatory cells and spares other immune cells such as CD4 and CD8. The news comes just on the heels of the company’s first-in-class, dual-functioning antibody, GIM-122, progressing to clinical trial for human testing.

BALTIMORE, MD, US, May 29, 2024 /EINPresswire.com/ — Linshom Medical, a Maryland-based startup developing a wearable respiratory monitoring system, announced today that it has been awarded a $100,000 grant from the Maryland Industrial Partnerships (MIPS) program to support a clinical study of its respiratory monitoring device.

The study, “Advanced Prediction of Respiratory Depression Episodes with Linshom Continuous Predictive Respiratory Monitoring (CPRM),” will evaluate the Linshom Medical device’s ability for early detection of patient respiratory decline in the Post Anesthesia Care Unit. Dr. Samuel M. Galvagno, Executive Vice Chair of Anesthesiology and Interim Chair of the Department of Anesthesiology, will lead this effort for UMSOM as the principal investigator.

NEW YORK – AMPEL BioSolutions is recruiting individuals with systemic lupus erythematosus (SLE) into an observational study of its blood-based prognostic gene expression assay LuGene to demonstrate a correlation between test results and standard clinical evaluations.

In addition, the company has been conducting a study to see whether different lupus subtypes as defined by its test correlate with therapeutic response.

These studies follow another one published in October in the journal Genome Medicine that showed evidence for eight transcriptionally defined SLE endotypes, or subgroups, and demonstrated LuGENE’s ability to predict patients at risk for episodes of worsening symptoms called flares with high sensitivity and specificity.

MANASSAS, Va.–(BUSINESS WIRE)–ATCC, the world’s premier biological materials management and standards organization, today announced that it has been awarded a task order with a ceiling value of $15.5 million, inclusive of base and options, by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Under this task order 75N93019D00002-75N93024F00001, ATCC will develop well-characterized challenge material (WCCM) for the In Vitro Assessment for Antimicrobial Activity (IVAAA) program. This program aims to evaluate candidate countermeasures against microbial pathogens and vectors, including those derived from clinical specimens. The assessments are conducted in vitro and focus on antiviral screening assays for biosafety level (BSL)-3/4 viruses relevant to human diseases, as well as other rapidly emerging viruses that employ similar assay methodologies.

The acquisition adds two proprietary clinical technologies to its portfolio and enhances Precision’s global capabilities in clinical data management, biostatistics and programming.

BETHESDA, Maryland, May 29 – Precision for Medicine, a global leader in biomarker-driven clinical research and development supporting life sciences companies, today announced the acquisition of Algorics, one of the fastest-growing clinical technologies and biometrics service providers to the biopharma industry. The addition of Algorics brings two innovative clinical technologies and further bolsters Precision for Medicine’s reach in the Asia-Pacific region. The acquisition also enhances Precision’s global capabilities in clinical data management, biostatistics, and programming.

BioHealth Innovation Inc. (BHI) congratulates the outstanding winners of the 2024 ICON Awards announced by the Maryland Tech Council. These awards recognize the incredible contributions of individuals and companies in the fields of technology and life sciences, highlighting their impact on millions of lives.

AstraZeneca: with a member of our BHI Board of Directors, Tyrell Rivers, Ph.D., has been honored as the Life Science Company of the Year. Their continued dedication to advancing healthcare through groundbreaking research and development is truly commendable.

Nanochon: We are particularly proud of Nanochon and Benjamin Holmes, the recipients of the Chief Executive Officer of the Year—Life Sciences award. Nanochon is a previous winner of our BioHealth Capital Region Crab Trap, and it’s exciting to see their sustained excellence and innovation being recognized on a larger stage.

Solaxa: A special congratulations to Solaxa, who was awarded the Venture Mentoring Services Venture of the Year. We are pleased to note that two members of Solaxa’s leadership team, Luis T. Gutierrez, Jr. and Jennifer Butler, are part of the BHI/Montgomery County Executive-In-Residence Program. This recognition underscores their remarkable leadership and commitment to advancing technology and life sciences.

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced data from the planned interim analysis of the exploratory open-label Phase 2a clinical study of SPN-817 for treatment-resistant seizures. The study is examining the safety and tolerability of SPN-817 as adjunctive therapy in adult patients with treatment-resistant seizures, as well as finding effective doses in various treatment-resistant seizure types. The interim analysis is as of May 1, 2024, and is based on 41 enrolled subjects, of which 19 completed the maintenance period. Of these 19 subjects, 16 subjects had focal seizures.

RICHMOND, Va., May 23, 2024 /PRNewswire/ — Activation Capital announces the launch of Frontier BioHealth, an educational and support program designed to provide highly specialized training, targeted mentorship, and relationship building to help scale pharmaceutical, biotech, medical device, and health-focused consumer products companies. The inaugural four-month program will be critical in bringing research-intense products and companies to market. It will broaden the continuum of regional early-stage support – additive to Virginia Commonwealth University’s proof of concept fund and newly launched pre-accelerator program – and continue to coalesce the emerging private investment ecosystem in Central Virginia.